Mainstay Medical is the most commercially advanced company in restorative neurostimulation for mechanical low back pain, a mechanistically distinct category from conventional SCS that targets the underlying multifidus dysfunction rather than pain signal masking. Its public status, two-year RCT data, and FDA approval give it a significant head start, though reimbursement access remains a key adoption constraint in the US market.